Qualitest Pharmaceuticals has announced that the FDA has approved dexamethasone elixir, USP, 0.5mg/ 5 mL
and OrsythiaT Tablets (levonorgestrel and ethinyl estradiol tablets, USP, 0.1
mg/0.02 mg).
Dexamethasone elixir is used to treat a variety of
conditions including endocrine disorders, rheumatic disorders, and collagen diseases.
OrsythiaT Tablets are indicated for the prevention of pregnancy in women who
elect to use oral contraceptives as a method of contraception.
The total IMS sales for dexamethasone elixir, USP, 0.5mg/ 5
mL and OrsythiaT Tablets (levonorgestrel and ethinyl estradiol tablets, USP, 0.1
mg/0.02 mg)for the 12-months ended March 31, 2011 are $4 million and $100
million, respectively.
